Isoniazid‐Dihydropyrimidinone Molecular Hybrids: Design, Synthesis, Antitubercular Activity, and Cytotoxicity Investigations with Computational Validation
ChemMedChem · 02.06.2025 · 20 (11)
DOI: 10.1002/cmdc.202400949 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2025-04. Verfasst von Gobind Kumar und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Physics, University of KwaZulu Natal, P/Bag X54001, Westville, Durban, 4000, South Africa. Hauptthemen laut MEDLINE: Antitubercular Agents, Isoniazid, Mycobacterium tuberculosis, Drug Design. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: National Research Foundation (SA), Association Vaincre la Mucoviscidose, Association Gregory Lemarchal.
Abstract (Originalsprache)
A new series of isoniazid‐dihydropyrimidinone molecular hybrids ( 8a – 8n ) were designed, synthesized and structurally characterized using different spectroscopic techniques viz., Fourier transform infrared spectroscopy, nuclear magnetic resonance (NMR), and high‐resolution mass spectrometry followed by their antitubercular evaluation including their precursors ( 4a – 4n ), and a standard antitubercular drug (isoniazid; INH). The molecular hybrids particularly 8g (minimum inhibitory concentration (MIC) = 6.25 μg mL −1 ), 8h (MIC = 1.56 μg mL −1 ), 8k (MIC = 0.78 μg mL −1 ), 8l (MIC = 6.25 μg mL −1 ), and 8n (MIC = 0.39 μg mL −1 ) demonstrated the most potent inhibitory activity against wild‐type M. tuberculosis mc 2 6230, disclosing 8n as the most potent compound in the series. However, the potent compounds lost their activity against three INH‐resistant M. tuberculosis strains mutated in katG . The more efficient compounds ( 8h , 8k , and 8n) were subsequently evaluated for their cytotoxicity against the THP‐1 human monocytic cell line. Furthermore, the stability studies of the most potent compound carried out using 1 H NMR, UV‐visible, and liquid chromatography‐mass spectrometry revealed their structural integrity. Finally, in silico molecular docking simulations were conducted to explore the binding orientations of the potent compounds in the active site of the target protein InhA while ADME/T (absorption, distribution, metabolism, excretion, and toxicity) and global reactivity parameters were explored to determine their drug‐likeness and stability profiles, respectively.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemistry and Physics, University of KwaZulu Natal, P/Bag X54001, Westville, Durban, 4000, South Africa.
- Centre National de la Recherche Scientifique UMR 9004, Institut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier, 1919 route de Mende, 34293, Montpellier, France.
- INSERM, IRIM, 34293, Montpellier, France.
- Department of Chemical Sciences, I. K. Gujral Punjab Technical University, Kapurthala, Punjab, 144603, India.
ORCID-Profile: Parvesh Singh
Förderung
- National Research Foundation (SA)
- Association Vaincre la Mucoviscidose
- Association Gregory Lemarchal
- Fondation pour la Recherche Médicale
Zitieren
APA
Kumar, G., Seboletswe, P., Mishra, S., Manhas, N., Ghumran, S., Kerru, N., Roquet-Banères, F., Foubert, M., Kremer, L., Bhargava, G., & Singh, P. (2025). Isoniazid‐Dihydropyrimidinone Molecular Hybrids: Design, Synthesis, Antitubercular Activity, and Cytotoxicity Investigations with Computational Validation. ChemMedChem, 20(11). https://doi.org/10.1002/cmdc.202400949
Vancouver
Kumar G, Seboletswe P, Mishra S, Manhas N, Ghumran S, Kerru N, et al. Isoniazid‐Dihydropyrimidinone Molecular Hybrids: Design, Synthesis, Antitubercular Activity, and Cytotoxicity Investigations with Computational Validation. ChemMedChem. 2025;20(11). doi:10.1002/cmdc.202400949
BibTeX
@article{Kumar2025,
author = {Kumar, Gobind and Seboletswe, Pule and Mishra, Sahil and Manhas, Neha and Ghumran, Safiyah and Kerru, Nagaraju and Roquet-Banères, Françoise and Foubert, Maëlle and Kremer, Laurent and Bhargava, Gaurav and Singh, Parvesh},
title = {Isoniazid‐Dihydropyrimidinone Molecular Hybrids: Design, Synthesis, Antitubercular Activity, and Cytotoxicity Investigations with Computational Validation},
journal = {ChemMedChem},
year = {2025},
volume = {20},
number = {11},
doi = {10.1002/cmdc.202400949}
}
EUVIMED